Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 57Urinary Bladder Neoplasms 11Carcinoma, Renal Cell 7Neoplasms 6Neoplasm Metastasis 5Melanoma 4Wilms Tumor 3Sarcoma 3Prostate Adenocarcinoma 3Lung Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 1Stage I Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Rhabdoid Tumor 1

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bladder Urothelial Carcinoma × Radiation × Genitourinary × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡